Zylidac will test whether optogenetic cell lines that hit 21 g/L in small-scale CHO runs can deliver higher-yield complex biologics at GMP scale.
|Articles|October 15, 2016
- BioPharm International-10-15-2016
- Volume 2016 eBook
- Issue 2
Cell Line Quality Technologies
Author(s)Susan Haigney
BioPharm International spoke with Selexis CEO and Chairman Igor Fisch, PhD about the latest cell-line development advances.
Advertisement
Chinese hamster ovary (CHO) cells are a common and stable option for mammalian expression systems, but what are the other cell line options in upstream processing and how do they compare in quality and stability to CHO cells? And what are the best techniques for ensuring quality and stability in cell-line development? BioPharm International spoke with Selexis CEO and Chairman Igor Fisch, PhD about the latest cell-line development advances and the analytical techniques companies can use to ensure quality and stability.
Articles in this issue
about 10 years ago
Investigation Effectiveness Drives Human Performance Excellenceabout 10 years ago
Data Integrity Challenges in Manufacturingabout 10 years ago
Evaluating Technology and Innovation in Biopharmaceutical Manufacturingabout 10 years ago
Seeking Accelerated Biosimilar Characterizationabout 10 years ago
Plant-Made Pharmaceuticals—Accelerating Drug Development Globallyabout 10 years ago
Testing the BrothAdvertisement
Related to this article
Nathan Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains where cold-chain planning still breaks down and why biopharma supply chain leaders should use AI to act on data sooner, with humans making the final call.
Revakinagene taroretcel (Encelto), the only FDA-approved MacTel therapy, slowed photoreceptor loss by up to 54.8% vs sham in phase 3 trials.
Backed by €400 million (US$449 million) in EU-cleared German aid, the new Frankfurt facility is designed to secure insulin supply for people with diabetes from 2032.
Nuravax will test AV-1959R in a 160-adult phase 2 trial to see whether the amyloid vaccine can prevent Alzheimer disease before symptoms begin.
Alexion’s ravulizumab won accelerated approval to reduce proteinuria in adults with IgA nephropathy after the Phase 3 I CAN trial showed a 43.4% placebo-adjusted reduction at Week 34.
Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains what is driving biopharma reshoring, how USMCA uncertainty complicates sourcing for biologics, and where cold-chain visibility still breaks down.
Advertisement
Advertisement
Trending on BioPharm International
1
Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP
2
BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial
3
FDA Grants Accelerated Approval to Ultomiris as First C5 Inhibitor for IgA Nephropathy
4
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
5